This platform gives access to an expanded complementary determining region (CDR) diversity that allows for rapid discovery of antibodies against (i) therapeutically relevant epitopes, (ii ...

Integral Molecular, a leader in antibody discovery and protein engineering, has launched a new technology-based service to ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

BI 771716, engineered using CDR-Life's proprietary technology and developed by Boehringer Ingelheim, represents a potential breakthrough in retinal therapy. Its unique antibody fragment design ...

Paratope-PLUS™ involves mutating each residue of an antibody's CDRs (Complementarity Determining Regions) to all 19 other amino acids, identifying every variant that retains or enhances function.